



100 Lancaster Ave.
Suite R215
Wynnewood, PA 19096

610.645.6796

www.curedm.com

Contact: Tava Shanchuk (LIMR)
shanchukt@mlhs.org

Donna Morrow (CureDM)
donna@curedm.com

CureDM, Inc. Announces Diabetes Research Collaboration with the Lankenau Institute For Medical Research

Wynnewood, Pennsylvania, September 8, 2006 -- CureDM, Inc., a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin, has moved from their offices in Chester to the Lankenau Institute for Medical Research (LIMR) in Wynnewood, PA. This move initiates a new diabetes research collaboration and opens up exceptional opportunities for the organization. These include gaining access to leading researchers, accelerating the development of novel therapeutic compounds for diabetes, and establishing new strategies for treating diseases of metabolism.

Lorraine V. Upham, President and CEO of CureDM, stated, "This new move not only gives us access to the terrific researchers here at LIMR but also brings us closer to the founding physicians of CureDM, Drs. Claresa Levetan and Rita El-Hajj, endocrinologists that work right here at Lankenau Hospital. We see this move as a great step forward toward changing diabetes from a chronic disease to a transient metabolic disorder."

The research team at CureDM has discovered a novel human peptide and a receptor associated with islet regeneration. This peptide called Human proIslet Peptide (HIP) stimulates the differentiation of adult pancreatic progenitor cells into insulin producing islets. It is hypothesized that restoration of pancreatic function can be achieved, without the use of stem cells, by clinical treatment with this peptide therapeutic. The CureDM approach is to restore, maintain and protect new insulin producing islets in patients with diabetes. For more information please visit their web site at: www.curedm.com.

Founded in 1927, the Lankenau Institute for Medical Research is an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of the Lankenau Hospital. Part of the Main Line Health System, LIMR is one of the few freestanding, hospital-associated medical research centers in the nation. The faculty and staff at the Institute are dedicated to advancing an understanding of the causes of cancer, heart disease, and diabetes. They use this information to help improve diagnosis and treatment of these diseases as well as find ways to prevent them. They are also committed to extending the boundaries of human health and well-being through technology transfer and education directed at the scientific, clinical, business and lay public communities. For more information visit our web site at www.limr.org.